Based on these findings, the recently published guidelines of the American Diabetes Association and the European Association for the Study of Diabetes recommended [74] either SGLT-2 inhibitors or GLP-1 agonists in patients with T2DM who are unable to achieve their target level of glycemic control with MET. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.